Interní Med. 2002; 4(10): 486-493

Diabetes mellitus a onemocnění kardiovaskulárního systému - II. Patogeneticky podložená prevence a léčba

doc. MUDr. Rudolf Chlup CSc1,3,2
1 Ústav fyziologie Lékařské fakulty Univerzity Palackého v Olomouci
2 II. interní klinika FN a LF UP Olomouc
3 Odborný léčebný ústav neurologicko-geriatrický Moravský Beroun

Keywords: diabetes mellitus, insulin resistance, macroangiopathy, hypertension, hyperlipoproteinemia.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chlup R. Diabetes mellitus a onemocnění kardiovaskulárního systému - II. Patogeneticky podložená prevence a léčba. Interní Med. 2002;4(10):486-493.

Patofyziologicky podložené terapeutické postupy, k nimž patří úprava životního stylu, komplementární léčba inzulinem a/nebo perorálními antidiabetiky, včasná léčba statiny a/nebo fibráty, léčba antiagregační, resp. antikoagulační, léčba inhibitory angiotenzin-konvertujícího enzymu, beta-blokátory, blokátory kalciového kanálu a dalšími antihypertoniky, mohou významně oddálit rozvoj kardiovaskulárních komplikací a prodloužit život diabetika.

Diabetes mellitus and cardiovascular disorders - II. Pathogenetically oriented therapeutic strategies

The pathogenetically oriented therapeutic strategies (implementation of a regular life style followed by complementary insulin treatment and/or oral antidiabetic drugs, statins and/or fibrates, antiagregants or anticoagulants, angiotensin converting enzyme inhibitors, betablockers, calcium channel blockers and/or other antihypertensive drugs) may delay the development of cardiovascular complications and extend the life expectancy of a diabetic patient.

Ústav fyziologie Lékařské fakulty Univerzity Palackého v Olomouci

II. interní klinika Fakultní nemocnice a Lékařské fakulty Univerzity Palackého v Olomouci

Odborný léčebný ústav neurologicko-geriatrický v Moravském Berouně

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Almdal T, Scharling H, Jensen JS, et al. Type II diabetes is an independent risk factor for myocardial infarction and death from ischemic heart disease in man and women. Abstract. Diabetologia 2002; 2: 94.
    2. American Diabetes Association: Concensus development conference on insulin resistance. Diabetes Care 1998: 310-314. Go to original source... Go to PubMed...
    3. Balletshofer BM, et al. Endothelial dysfunction is detectable in young normotensive first - degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784. Go to original source... Go to PubMed...
    4. Bergman RN, et al. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: 667. Go to original source... Go to PubMed...
    5. Cauza E, Hanusch-Enserer U, Strassser B, et al. Effects of resistence training on glycemic control in type 2 diabetes mellitus. Diabetologia 2002; 2: 34.
    6. Cífková R. za členy společné pracovní skupiny: Prevence ischemické choroby srdeční v dospělém věku. Diab Metab Endokr Výž 2001; 1: 13-27.
    7. Češka R. Léčba diabetické dyslipoproteinémie. Kapitoly Kardiol 2001; 3/2: 14-19.
    8. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    9. De Fronzo RA, et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223. Go to original source... Go to PubMed...
    10. Despres JP, LaMarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957. Go to original source... Go to PubMed...
    11. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project randomised trial (CAPP). Lancet 1999; 353: 611-616.
    12. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116. Go to original source...
    13. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistence in essential hypertension. N Engl J Med 1987; 317: 317-350. Go to original source... Go to PubMed...
    14. Feskens EJM, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler Tromb 1994; 14: 1641-1647. Go to original source... Go to PubMed...
    15. Gaede P, Vedel P, Larsen N, et al. The Steno-2 study: intensified multifactorial intervention reduced the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria. Abstract. Diabetologia 2002; 45/2: 63.
    16. Haffner SM, Kennedy E, Gonzalez C, et al. A prospective adalysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19/10: 1138-1141. Go to original source... Go to PubMed...
    17. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. Go to original source... Go to PubMed...
    18. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardivascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259. Go to original source...
    19. Helge JW, Dela F. Training and insulin sensitivity: effect of muscle phospholipid and triacylglycerol fatty acid composition and total muscle triacylglycerol content. Abstract. Diabetologia 2002; 45/2: 34.
    20. Hřebíček J, Janout B, Malinčíková J, et al. Detection of insulin resistence by simple quantitative sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metabol 2002; 87: 144-147. Go to original source... Go to PubMed...
    21. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25/7: 1129-1134. Go to original source... Go to PubMed...
    22. Hypertension Optimal Treatment Trial (HOT). Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    23. Chen W, Srinivasan SR, Elkasabany A, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (syndrome X) between young parents and their offspring: the Bobalusa Heart Study. Atherosclerosis 1999; 145: 197-205. Go to original source... Go to PubMed...
    24. Chlup R. Současné možnosti prevence diabetes mellitus 1. a 2. typu. Kapitoly Kardiol 2001; 3/2: 36-39.
    25. Chlup R, Bruns W. Patofyziologický přístup k léčbě diabetu 2. typu. Intern Med 1999; 4: 27-35.
    26. Chlup R, Vaverková H, Bartek J: Complementary insulin therapy improves blood glucose and serum lipid perameters in type 2 (non-insulin-dependent) diabetic patients. I. Effect on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105/2: 70-73. Go to original source... Go to PubMed...
    27. ImperatoreB, Ricardi G, Iovine C, et al. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998; 21: 549-654. Go to original source... Go to PubMed...
    28. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-865.
    29. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A simple, accurate method for assessing insulin sensitivity in humans. Clin Endocrinol Metabol 2000; 85/7: 2402-2410. Go to original source... Go to PubMed...
    30. Kernan WN, Inzucchi SE, Viscoli CM, et al. Insulin resistence and risk for stroke. Neurology 2002; 59/6: 809. Go to original source... Go to PubMed...
    31. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456. Go to original source... Go to PubMed...
    32. Lemieux I, Lamarche B, St-Pierre A, et al. Low HDL cholesterol without vs. with features of the atherogenic metabolic triad and its impact on IHD risk: the Québec cardiovascular study. Abstract. Diabetologia 2002; 45/2: 63-64.
    33. Lichnovská R, Gwozdziewiczová S, Hřebíček J. Gender differences in metabolic variables related to insulin resistance in elderly hyperlipemic non-diabetic subjects. Cardiovascular Diabetology v tisku.
    34. Linhart A, Paleček T, Aschermann M. Koronární postižení při diabetu - prevence a léčba. Kapitoly Kardiol 2001; 3/2: 20-26.
    35. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28/7: 412-419. Go to original source... Go to PubMed...
    36. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. J Amer Med Ass 2000; 283: 221-228. Go to original source... Go to PubMed...
    37. Meigs JB, Nathan DM, D´Agostino RB, et al. Fasting and postchallenge glycemia and cardiovascular disease risk. Diabetes Care 2002; 25: 1845-1850. Go to original source... Go to PubMed...
    38. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820. Go to original source... Go to PubMed...
    39. Nilsson PM. Hypertention in diabetes - favourable trends in clinical control in repeated national surveys from Sweden. Abstract. Diabetologia 2002; 45/2: 64.
    40. Oerry C. Report of 6th Scientific Meeting of the Hypertension in Diabetes (HID). Study Group of the EASD in Edinburgh. Abstract. Diabetologia 2001; 44/11: 57.
    41. Olšovský J. Vliv antihypertenzní terapie na inzulinovou rezistenci. Vnitřní Lék 1999; 45/11: 670-672.
    42. Pelikánová T. Ischemická choroba srdeční u nemocných s diabetem 2. typu. Diab Metab Endokr Výž 1999; 2/4: 161-169.
    43. Piarulli FN, Marolla ME, Bax G, et al. Insulin reduce progression of carotid stenosis in type 2 diabetes mellitus: a three years prospective study. Abstract. Diabetologia 2002; 45/2: 95.
    44. Reaven GM, Chen YDI, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141-146. Go to original source... Go to PubMed...
    45. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistence and the sympathoadrenall system. N Engl J Med 1996; 334: 374-381. Go to original source... Go to PubMed...
    46. Ruige JB, Assendelft WJJ, Dekker JM, et al. Insulin and risk of cardiovascular disease. A meta-analysis. Circulation 1998; 97: 996-1991. Go to original source... Go to PubMed...
    47. Rybka J, Adamíková A. Syndrom diabetické nohy. Kapitoly Kardiol 2001; 3/2: 28-31.
    48. Shulman GI. Cellular mechanism of insulin resistence. J Clin Invest 2000; 106: 171-176. Go to original source... Go to PubMed...
    49. Scheen AJ, Van Gaal LF, et al. Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI Survey. Diabetologia 2002; 45/2: 63.
    50. Solerte SB, Fioravanti M. Human insulin up-regulates the release of Vascular Endothelial Growth Factor (VEGF) from immune cells in hyperinsulinemic microalbuminuria type 2 diabetic patients. Diabetologia 2002; 45/2: 35.
    51. Stout RW. Overview of the association between insulin and atherosclerosis. Metabolism 1985; 34/12 (Suppl. 1): 7-12. Go to original source... Go to PubMed...
    52. Turner R, Tchobroutsky G, Slama G, et al. Vascular complications of diabetes. Éditions pradel Paris 1994: 1-166.
    53. Šejda T. Rostlinné steroly a stanoly v prevenci ischemické choroby srdeční. Diab Metab Endokr Výž 2001; 4/2: 140-144.
    54. The Framingham Study. Circulation 1979; 59: 8-13.
    55. The UK Prospective Diabetes Study (UKPDS): Effect of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    56. The UK Prospective Diabetes Study (UKPDS): Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720. Go to original source...
    57. The UK Prospective Diabetes Study (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    58. The UK Prospective Diabetes Study (UKPDS) (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713. Go to original source...
    59. Vaverková H, Chlup R, Ficker L, et al. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effect on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105/2: 74-77. Go to original source... Go to PubMed...
    60. Welborn TA, Knuiman MW, Ward N, et al. Serum insulin is a risk marker for coronary heart disease mortality in men but not in women. Diabetes Res Clin Pract 1994; 26: 51-59. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.